Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=44 Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
N/A N=224 A Prospective Randomized Study for Comparison of Y-Composite Grafts
Coronary Artery Disease
Primary: 1 Year Graft Patency Rates — 97.1; 97.1 percentage of distal anastomoses
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
N/A N=116 Comparison of Bidirectional Palpation Test and Transit Time Flow Measurement for LIMA-LAD Graft Patency
Coronary Arterial Disease (CAD) · Coronary Artery Bypass · LIMA
Primary: Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency — 2; 2; 2; 2 Participants — p=<0.001
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 3 N=293 GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
N/A N=207 Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.
Peripheral Arterial Occlusive Disease
Primary: Number of Participants With Primary Patency — 70; 89 Participants — p=<.0001
N/A N=33 HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis
End Stage Renal Disease (ESRD)
Primary: Mortality — 18.8; 29.4 percentage of participants who died — p=0.48
Phase 3 N=138 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 83.6 percentage of participants
N/A N=103 Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
N/A N=51 Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Phase 3 N=288 Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
Delayed Graft Function
Primary: Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant — 35.9; 41.7; 33.8; 39.6 percentage of participants — p=0.3983
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
Phase 2 N=15 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
Chronic Granulomatous Disease
Primary: Percentage of Participants With Engraftment — 100 percentage of participants
Phase 2 N=74 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants
N/A N=86 Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Early Allograft Dysfunction · Ischemic Reperfusion Injury · Liver Transplantation
Primary: Early Allograft Dysfunction — 6; 18 Participants
N/A N=733 Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
Cardiovascular Disease · Coronary Artery Disease
Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…
Phase 2 N=114 Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Ischemia-Reperfusion Injury · Lung Transplantation
Primary: PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours — 346.3; 337.9; 320.1; 307.3 ratio of PaO2/FiO2 — p=0.8541
Phase 2 N=70 C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
End Stage Renal Disease · Kidney Failure · Delayed Graft Function
Primary: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. — 29; 32 Participants
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 2 N=1 The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
Clostridium Difficile Infection · C.Difficile Diarrhea · CDI
Primary: Assess Efficacy of Oral FMT on Composition and Function of the Gut Microbiota Compared to Placebo.
Phase 2 N=74 Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
Ischemia-Reperfusion Injury · Kidney Diseases
Primary: Creatinine Clearance (CrCl) in the Immediate Post-transplant Period — 5.11; 7.44; 6.30; 9.66 mL/min — p=0.9076